Adjuvant Chemotherapy for Intrahepatic Cholangiocarcinoma: Far from a Clinical Consensus.

Wei‐Feng Qu,Wei‐Ren Liu,Ying‐Hong Shi

DOI: https://doi.org/10.21037/hbsn-21-362

2021-01-01

HepatoBiliary Surgery and Nutrition

Abstract:Intrahepatic cholangiocarcinoma (iCCA), which arises from the second-order bile tracts, is the second most common primary liver cancer following hepatocellular carcinoma (1).As a subtype of biliary tract cancer (BTC), iCCA is a highly lethal neoplasm with an increasing incidence and mortality.Surgery remains the mainstay for curative intention.However, the postoperative prognosis of iCCA patients is dismal, with a 3-year recurrence rate over 50% and a median overall survival (OS) time of approximately 30 months (2).In an attempt to improve the clinical outcome of iCCA patients, considerable efforts have been made to explore the optimal adjuvant therapy.So far, most studies focusing on the adjuvant treatment for iCCA were retrospective and covered local to systematic therapy, including external beam radiation, transarterial chemoembolization (TACE), chemotherapy, targeted therapy, and immune therapy (3).Previous studies have suggested that patients who received adjuvant therapy were characterized by an advanced tumor stage (4), and patients with adverse prognostic factors such as high tumor burden (5) were more likely to benefit from adjuvant treatment.Notably, Miura et al. explored a significant improvement in median OS after adjuvant chemotherapy a m o n g p a t i e n t s w i t h l y m p h o i d m e t a s t a s i s a f t e r resection (6).However, the selection bias and insufficient treatment information in this retrospective analysis prevented its conclusions from being converted into widespread clinical utilization.